Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

Cited In for PubMed (Select 20187195)

1.

Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.

Brisset JC, Hoff BA, Chenevert TL, Jacobson JA, Boes JL, Galbán S, Rehemtulla A, Johnson TD, Pienta KJ, Galbán CJ, Meyer CR, Schakel T, Nicolay K, Alva AS, Hussain M, Ross BD.

PLoS One. 2015 Apr 10;10(4):e0123877. doi: 10.1371/journal.pone.0123877. eCollection 2015.

2.

Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.

Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD.

PLoS One. 2015 Mar 27;10(3):e0122151. doi: 10.1371/journal.pone.0122151. eCollection 2015.

3.

Nuclear Overhauser Enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology.

Paech D, Burth S, Windschuh J, Meissner JE, Zaiss M, Eidel O, Kickingereder P, Nowosielski M, Wiestler B, Sahm F, Floca RO, Neumann JO, Wick W, Heiland S, Bendszus M, Schlemmer HP, Ladd ME, Bachert P, Radbruch A.

PLoS One. 2015 Mar 19;10(3):e0121220. doi: 10.1371/journal.pone.0121220. eCollection 2015.

4.

Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.

Huang RY, Neagu MR, Reardon DA, Wen PY.

Front Neurol. 2015 Feb 23;6:33. doi: 10.3389/fneur.2015.00033. eCollection 2015. Review.

5.

sfDM: Open-Source Software for Temporal Analysis and Visualization of Brain Tumor Diffusion MR Using Serial Functional Diffusion Mapping.

Ceschin R, Panigrahy A, Gopalakrishnan V.

Cancer Inform. 2015 Feb 1;14(Suppl 2):1-9. doi: 10.4137/CIN.S17293. eCollection 2015.

6.

Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.

Ellingson BM, Kim E, Woodworth DC, Marques H, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Int J Oncol. 2015 May;46(5):1883-92. doi: 10.3892/ijo.2015.2891. Epub 2015 Feb 11.

7.

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.

Wen Q, Jalilian L, Lupo JM, Molinaro AM, Chang SM, Clarke J, Prados M, Nelson SJ.

J Neurooncol. 2015 Jan;121(2):331-9. doi: 10.1007/s11060-014-1636-6. Epub 2014 Oct 29.

8.

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii36-47. doi: 10.1093/neuonc/nou226.

PMID:
25313237
9.

Emerging techniques and technologies in brain tumor imaging.

Ellingson BM, Bendszus M, Sorensen AG, Pope WB.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii12-23. doi: 10.1093/neuonc/nou221.

PMID:
25313234
10.

Advanced magnetic resonance imaging of the physical processes in human glioblastoma.

Kalpathy-Cramer J, Gerstner ER, Emblem KE, Andronesi OC, Rosen B.

Cancer Res. 2014 Sep 1;74(17):4622-37. doi: 10.1158/0008-5472.CAN-14-0383. Review.

PMID:
25183787
11.

Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma.

LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2014 Dec;16(12):1599-606. doi: 10.1093/neuonc/nou142. Epub 2014 Jul 24.

PMID:
25059209
12.

Imaging biomarkers for antiangiogenic therapy in malignant gliomas.

Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM.

CNS Oncol. 2013 Jan;2(1):33-47. Review.

13.

Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG.

Neuro Oncol. 2014 Jun;16(6):880-8. doi: 10.1093/neuonc/not216. Epub 2014 Jan 15.

14.

Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma.

Woodworth DC, Pope WB, Liau LM, Kim HJ, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM.

J Neurooncol. 2014 Feb;116(3):551-8. doi: 10.1007/s11060-013-1320-2. Epub 2013 Dec 7.

15.

Challenges for the functional diffusion map in pediatric brain tumors.

Grech-Sollars M, Saunders DE, Phipps KP, Kaur R, Paine SM, Jacques TS, Clayden JD, Clark CA.

Neuro Oncol. 2014 Mar;16(3):449-56. doi: 10.1093/neuonc/not197. Epub 2013 Dec 4.

16.

The correlation between apparent diffusion coefficient and tumor cellularity in patients: a meta-analysis.

Chen L, Liu M, Bao J, Xia Y, Zhang J, Zhang L, Huang X, Wang J.

PLoS One. 2013 Nov 11;8(11):e79008. doi: 10.1371/journal.pone.0079008. eCollection 2013. Review.

17.

Diffusion-Weighted MRI as a Biomarker of Tumor Radiation Treatment Response Heterogeneity: A Comparative Study of Whole-Volume Histogram Analysis versus Voxel-Based Functional Diffusion Map Analysis.

Lemasson B, Galbán CJ, Boes JL, Li Y, Zhu Y, Heist KA, Johnson TD, Chenevert TL, Galbán S, Rehemtulla A, Ross BD.

Transl Oncol. 2013 Oct 1;6(5):554-61. eCollection 2013.

18.

Diffusion-weighted MRI as a biomarker for treatment response in glioma.

Schmainda KM.

CNS Oncol. 2012 Nov;1(2):169-80. Review.

19.

Parameterizing the Logistic Model of Tumor Growth by DW-MRI and DCE-MRI Data to Predict Treatment Response and Changes in Breast Cancer Cellularity during Neoadjuvant Chemotherapy.

Atuegwu NC, Arlinghaus LR, Li X, Chakravarthy AB, Abramson VG, Sanders ME, Yankeelov TE.

Transl Oncol. 2013 Jun 1;6(3):256-64. Print 2013 Jun.

20.

Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics.

Rodriguez Gutierrez D, Manita M, Jaspan T, Dineen RA, Grundy RG, Auer DP.

Neuro Oncol. 2013 Aug;15(8):981-9. doi: 10.1093/neuonc/not034. Epub 2013 Apr 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk